

FINAL REPORT

FOR CRADA NO. C-06-07

BETWEEN

BROOKHAVEN SCIENCE ASSOCIATES

AND

NANO -LIFE SCIENCES, INC.

Project Entitled:

Rapid Cycling Medical Synchrotron

Brookhaven PI: Stephen Peggs

Submitted by: Michael J. Furey
Manager, Research Partnerships
Brookhaven National Laboratory

Notice: This manuscript has been authored by employees of Brookhaven Science Associates, LLC under Contract No. DE-SC0012704 with the U.S. Department of Energy. The publisher by accepting the manuscript for publication acknowledges that the United States Government retains a non-exclusive, paid-up, irrevocable, world-wide license to publish or reproduce the published form of this manuscript, or allow others to do so, for United States Government purposes.

DISCLAIMER

This work was prepared as an account of work sponsored by an agency of the United States Government. Neither the United States Government nor any agency thereof, nor any of their employees, nor any of their contractors, subcontractors or their employees, makes any warranty, express or implied, or assumes any legal liability or responsibility for the accuracy, completeness, or any third party's use or the results of such use of any information, apparatus, product, or process disclosed, or represents that its use would not infringe privately owned rights. Reference herein to any specific commercial product, process, or service by trade name, trademark, manufacturer, or otherwise, does not necessarily constitute or imply its endorsement, recommendation, or favoring by the United States Government or any agency thereof or its contractors or subcontractors. The views and opinions of authors expressed herein do not necessarily state or reflect those of the United States Government or any agency thereof.

**FINAL REPORT
FOR CRADA NO. C-06-07
BETWEEN
BROOKHAVEN SCIENCE ASSOCIATES
AND
NANO-LIFE SCIENCES, INC.**

Project Entitled: Rapid Cycling Medical Synchrotron

Brookhaven PI: Stephen Peggs

Submitted by: Michael J. Furey
Manager, Research Partnerships
Brookhaven National Laboratory

Notice: This manuscript has been authored by employees of Brookhaven Science Associates, LLC under Contract No. DE-AC02-98CH10886 with the U.S. Department of Energy. The publisher by accepting the manuscript for publication acknowledges that the United States Government retains a non-exclusive, paid-up, irrevocable, world-wide license to publish or reproduce the published form of this manuscript, or allow others to do so, for United States Government purposes.

DISCLAIMER

This work was prepared as an account of work sponsored by an agency of the United States Government. Neither the United States Government nor any agency thereof, nor any of their employees, nor any of their contractors, subcontractors or their employees, makes any warranty, express or implied, or assumes any legal liability or responsibility for the accuracy, completeness, or any third party's use or the results of such use of any information, apparatus, product, or process disclosed, or represents that its use would not infringe privately owned rights. Reference herein to any specific commercial product, process, or service by trade name, trademark, manufacturer, or otherwise, does not necessarily constitute or imply its endorsement, recommendation, or favoring by the United States Government or any agency thereof or its contractors or subcontractors. The views and opinions of authors expressed herein do not necessarily state or reflect those of the United States Government or any agency thereof.



Memo

Date: December 21, 2009

To: M. J. Furey

From: S. Peggs

Subject: CRADA No. BNL-C-06-07 Between BNL and Nano-Life Sciences, "Rapid Cycling Medical Synchrotron."

The term of the subject CRADA expired as of October, 2007. The "Funds-in" for this CRADA were initially expected to be \$5,195,436, while in fact Nano-Life had provided a net total of only \$290,156 by the termination of the CRADA. This termination was initiated by BNL. Nano-Life has since ceased operation, after the suicide of its CEO.

This memo serves as the final abstract of the CRADA, insofar as it was abandoned at an early stage. Because the CRADA was terminated at such an early stage, and because of the demise of Nano-Life, there is no possibility of a jointly filed final report.

Significant accomplishments. The goal of this CRADA was to perform early prototyping on the Rapid Cycling Medical Synchrotron, leading to more accurate cost and schedule estimates. Some progress was made in this direction.

Significant problems. Nano-Life first deposited installments on schedule, but quickly fell behind. Work slowed down at BNL, and then eventually ceased when it became clear that the CRADA could not be completed for want of financial support. The final act was for BNL to return \$109,845 of unspent funds to Nano-Life. Larry Welch, the Nano-Life CEO, committed suicide a few months later.

Industry benefits. None.

Laboratory benefits. The modest progress that was made in laying down rapid prototyping plans for the RCMS could easily be picked up where they ceased. The RCMS is ready to take the next step.

Recommended follow-on work. Identify a new CRADA partner, or another mechanism, through which early RCMS prototyping could be resumed.

Potential benefits from pursuing follow-on work. Rapid prototyping leading to first implementation and commissioning of the RCMS.